Global Hemophilia Drugs Market Growth 2023-2029

Global Hemophilia Drugs Market Growth 2023-2029

The hemophilia treatment drugs market is experiencing entry of a large number of new drugs in the market. Few of them have already arrived and other long lasting clotting factors and more promising drugs are on their way to get launched in this market. For instance, follow up data from phase I/II study of hemophilia medicine ‘Emicizumab’ by Roche has demonstrated promising results regarding safety and prophylactic efficiency in people with severe hemophilia A. Another example is of ‘Eloctate’ for type A and ‘Aprolix’ for type B hemophilia, respectively. These two newly arrived biogen products are opposed to commonly prescribe course of three infusions per week as they are longer-acting than traditional treatments and require only one to two infusions per week, due to their new mechanism of action.

LPI (LP Information)' newest research report, the “Hemophilia Drugs Industry Forecast” looks at past sales and reviews total world Hemophilia Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Hemophilia Drugs sales for 2023 through 2029. With Hemophilia Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hemophilia Drugs industry.

This Insight Report provides a comprehensive analysis of the global Hemophilia Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hemophilia Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Hemophilia Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hemophilia Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hemophilia Drugs.

The global Hemophilia Drugs market size is projected to grow from US$ 12460 million in 2022 to US$ 16680 million in 2029; it is expected to grow at a CAGR of 16680 from 2023 to 2029.

With increasing attention on prophylactic treatment, the market for hemophilia drugs is estimated to have a positive outlook over the coming years. The prophylactic treatment approach prevents spontaneous bleeding episodes, significantly improves the quality of life in terms of physical activities, and maintains the level of clotting factors above a baseline. According to the studies conducted by the US National Library of Medicine determined that the savings on prophylactic treatment be approximately USD 8,312 to USD 17,675 per bleeding episode in a person. Moreover, this line of treatment reduces joint damage and suffering from pain. Several of such long-acting therapeutics are under development and expected to be launched over the next four years. The shift in preference for prophylactic treatment due to its advantages will drive this market’s growth over the forecast period.

This report presents a comprehensive overview, market shares, and growth opportunities of Hemophilia Drugs market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Hemophilia A
Inhibitors
Hemophilia B
Von Willebrand Disease

Segmentation by application
Recombinant Therapies
Plasma-Derived Therapies

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Baxalta
Bayer
CSL Behring
Pfizer
Alnylam Pharmaceuticals
BioMarin
Catalyst Biosciences
Dimension Therapeutics
F. Hoffmann-La Roche
Grifols
Octapharma
Sangamo Biosciences
Spark Therapeutics
Swedish Orphan Biovitrum

Key Questions Addressed in this Report

What is the 10-year outlook for the global Hemophilia Drugs market?

What factors are driving Hemophilia Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Hemophilia Drugs market opportunities vary by end market size?

How does Hemophilia Drugs break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.